| dc.description.abstract | Gastric cancer is known as the third most common cancer in the world, and many efforts are being made to find suitable treatments for it all over the world. In recent years, the role of plasma membrane carriers (The solute carrier) in cancer has been noticed. Meanwhile, SLC16A family members play an important role in tumorigenesis and tumor progression. However, the precise role of distinct members in the SLC16A family in human cancer remains unclear. Integrated bioinformatics analysis to identify therapeutic targets for some cancers based on transcriptomics, proteomics and high-throughput sequencing can help us gain new information and understand potential molecular mechanisms. In the present study, we attempted to knock down the expression of this gene in gastric cancer cell lines to investigate the effect of reducing the expression of this gene on the ability of gastric cancer cells to survive, grow and metastasize.
Matherial ans methods: Firstly, gastric cancer cell lines (KATO) were cultured in RPMI + 10% FBC medium and then synthetic si-RNA of SLC16A13 antigen was transfected in the cell lines. Then the effect of this treatment on the process of cell death and apoptosis was investigated by MTT and flow cytometry tests. SCRATCH test was also used to investigate the role of this treatment on the migration ability of cancer cells. Also, the effect of this treatment on the change of target gene expression will be analyzed by western blot test and Real Time PCR. Finally, the expression changes of genes involved in apoptosis and cell migration were evaluated by RT-PCR method.
Results: According to the results obtained from the present study, the decrease in the expression of the SLC16A13 gene causes an increase in cell death in cells, but according to the results of the SCRATCH test, the decrease in the expression of this gene has no effect on the ability of cells to migrate. | en_US |
